Potential of afatinib in the treatment of patients with HER2-positive breast cancer - Wikidata - wikimedia - TriplyDB

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

http://www.wikidata.org/entity/Q26999050

about

Clinical pathologies of breast cancer in the elderly and youths and their prognosis.Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer Recent advances in the development of breast cancer vaccines.Metastatic and triple-negative breast cancer: challenges and treatment options Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer

P2860

Q33722556-BDDE9B15-D106-4924-899E-03BC183FA619 Q34104079-CFF251A6-C91F-4562-A58D-D5A801E4B804 Q34268618-19C7ECAD-33C5-40AE-A17C-128AAF62C694 Q34379303-B89F2E0F-20D2-4C1A-A61F-35471E6F3584 Q57105258-4C6217FD-A99F-4081-99D9-E90893B05FB9 Q58801774-FB9E4EFA-F7F9-4E67-A9F9-ACB0687B8815

P2860

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

http://www.wikidata.org/entity/Q26999050

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@ast

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@en

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@nl

type

label

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@ast

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@en

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@nl

prefLabel

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@ast

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@en

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@nl

P1433

Q26999050-9DB5849E-FF4B-49E7-B742-8A7B21E0A6E2

P1476

Q26999050-D9896703-5563-4DAC-8F94-2DCF48BEDA95

P2093

Q26999050-4253D2E7-5A0F-41F6-8401-39CC575C4643

Q26999050-DC4BF16A-C48B-42B8-B215-1E4EFCAC0A87

Q26999050-EF2829B2-B97C-4ABF-A0E8-1E3A111D1344

Q26999050-F99EF482-A673-44B2-89BE-1A228907E401

P2860

Q26999050-09C8E5D7-4DA2-46F5-9321-2C1CA78BF6E7

Q26999050-0D692D7B-678E-43C9-B44F-76CE567A0655

Q26999050-117DBA50-7E86-409C-B5A5-C15992EB6601

Q26999050-27603397-3E81-487C-99CF-4F6D6CB68D11

Q26999050-28793FD9-4CF6-4569-B714-E23D312DE78C

Q26999050-31AE387C-EB48-4CCD-BC98-6CB505FCE1E2

Q26999050-49F08A4E-B745-44A3-B49C-5A3E24FD73F0

Q26999050-4ECD019C-D33A-4951-8B57-3DDE0FFD97B6

Q26999050-84B44815-B09C-46FC-BAE9-3E754A32B42C

Q26999050-870880E7-9888-4C83-A38D-8E66BE42D655

P304

Q26999050-D7036106-A7E7-475B-BF5E-3F7EEEB32180

P31

Q26999050-CDA22DA2-5012-4A58-85E1-5030994EB144

P356

Q26999050-FDBB46E0-D837-40A2-9D9E-F43622F44CE2

P407

Q26999050-673D428C-9005-4C0C-9BF5-E2D12B571B54

P478

Q26999050-6581F2F7-C4FE-4E22-89D8-E326361A509D

P50

Q26999050-80622BAF-9256-4252-BF11-CABE64890015

Q26999050-AA247404-0336-48BA-A8DD-95F556A7E949

Q26999050-AB7A2A2C-FC08-411E-B090-C9ABEADD7BED

Q26999050-B672ED26-B495-429B-A388-2B8E3EBF1B20

P577

Q26999050-7DBB105C-BEAF-4F52-A02B-1C389C38AE6F

P698

Q26999050-906BA38F-8B5B-4ED6-AFFE-2CC546F27BEB

P921

Q26999050-63b7e85f-41d8-615f-3082-dd77b1221cee

P932

Q26999050-8014CA2E-E220-4460-B410-4CEAAB4E9D24

P356

P1433

Breast Cancer: Targets and Therapy

P1476

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

@en

P2093

Elena Geuna

http://www.w3.org/2001/XMLSchema#string

Filippo Montemurro

http://www.w3.org/2001/XMLSchema#string

Giorgio Valabrega

http://www.w3.org/2001/XMLSchema#string

Massimo Aglietta

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

Untangling the ErbB signalling network

P304

131-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BCTT.S25868

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Giorgio Valabrega

Filippo Montemurro

P577

2012-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24367201

http://www.w3.org/2001/XMLSchema#string

P921

Her2-receptor positive breast cancer

P932

3846413

http://www.w3.org/2001/XMLSchema#string